Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Can-Fite BioPharma Ltd.CANF · Entity 8141 | CEO, CFO and COO | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Can-Fite BioPharma Ltd.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $2.04 · Expires 2036-06-04 | Direct | 33,132 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 24,000 · Balance 33,132 F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee. F2: The options will vest in sixteen equal quarterly installments beginning 09/04/2026 and ending 04/06/2030, subject to the Reporting Person's continued service to the Issuer as of such vesting date. F3: The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 5.94, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on June 5, 2026, which was NIS 2.908 = USD 1.00. |
Filing footnotes · ownership attribution and instrument terms
F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
F2: The options will vest in sixteen equal quarterly installments beginning 09/04/2026 and ending 04/06/2030, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F3: The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 5.94, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on June 5, 2026, which was NIS 2.908 = USD 1.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:15 UTC | Can-Fite BioPharma Ltd. CANF · Entity 8141 | GrantOptions to Purchase Ordinary Shares · Derivative | 24,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001213900-26-066290 · ownership.xml · derivative · entry 1 Farbstein Motti · CIK 0002116362 · CEO, CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,132 Underlying: Ordinary Shares · 24,000 shares Expires 2036-06-04 F1 · security: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee. F2 · security: The options will vest in sixteen equal quarterly installments beginning 09/04/2026 and ending 04/06/2030, subject to the Reporting Person's continued service to the Issuer as of such vesting date. F3 · derivative.exercise_price: The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 5.94, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on June 5, 2026, which was NIS 2.908 = USD 1.00. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.